Search results for "Immunogen"

showing 10 items of 226 documents

B and T cell immune responses elicited by the BNT162b2 (Pfizer–BioNTech) COVID-19 vaccine in nursing home residents

2021

ABSTRACTObjectivesThe immunogenicity of the BNT162b2 COVID-19 vaccine is understudied in elderly people with comorbidities. We assessed SARS-CoV-2-S-targeted antibody and T cell responses following full vaccination in nursing home residents (NHR).MethodsWe recruited 60 NHR (44 female; median age, 87.5 years), of whom 10 had previously had COVID-19, and 18 healthy controls (15 female; median age, 48.5 years). Pre- and post-vaccination blood specimens were available for quantitation of total antibodies binding RBD and enumeration of SARS-CoV-2-S-reactive IFN-γ CD4+ and CD8+ T cells by flow cytometry.ResultsThe seroconversion rate in presumably SARS-CoV-2 naïve NHR (95.3%), either with or with…

medicine.diagnostic_testbiologybusiness.industryImmunogenicityT cellFlow cytometryVaccinationmedicine.anatomical_structureImmune systemImmunologybiology.proteinMedicineSeroconversionAntibodybusinessCD8
researchProduct

Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future

2014

Cancer immunotherapy seeks to elicit or augment the antitumor immune response in a patient in order to enlist the help of the patient’s own immune system for tumor control. In this context, immune monitoring provides evidence of immunogenicity, guides the choice and dosage of antigens, assesses the effects of immune modulators and therapy combinations, and has the potential to reveal early biomarkers of clinical efficacy. In view of their role in the anticancer immune response, the quantity and quality of tumor antigen-specific effector CD4+ and CD8+ T cells are of particular interest, and characterization of regulatory T cells and myeloid-derived suppressor cells is increasingly relevant. …

medicine.diagnostic_testbusiness.industrymedicine.medical_treatmentImmunogenicityContext (language use)ImmunotherapyFlow cytometryImmune systemCancer immunotherapyAntigenImmunologyMedicinebusinessCancer immunology
researchProduct

Phages as Promising Biomedical Tools

2018

medicine.drug_classImmunogenicityAntibioticsmedicineLysinGeneral MedicineMicrobiomeBiologyEndocytosisPhenotypeMicrobiologyBiomedical Journal of Scientific & Technical Research
researchProduct

General considerations in the interpretation of I-J genetic restrictions: evidence that the antigen-binding chain of antigen-specific T-suppressor fa…

1987

SUMMARY (CBA × B10)F1 [(H-2k x H-2b)] mice produce two types of antigen-specific T-suppressor factor (TsF), which can be separated by affinity chromatography on anti-I-J monoclonal antibody. After reduction and alkylation, both chains of F1 TsF are required for biological activity. However, the antigen-binding chain (AgBC) of F1 TsFk (AgBCk) is only complemented by I-Jk and likewise for F1 TsFb. In other words, interchain complementation shows the same genetic restriction in interchain complementation in parental and F1 mice. F1 TsF bearing, for example, I-Jk (TsFk), interacts with haptenized ‘antigen-presenting cells’ (‘APC’) of both parental haplotypes, and may be described as showing dua…

medicine.drug_classImmunologyAntigen-Presenting CellsImmunogeneticsBiologyMonoclonal antibodyModels BiologicalEpitopesMiceStructure-Activity RelationshipAntigenAffinity chromatographySpecies SpecificityGeneticsmedicineSuppressor Factors ImmunologicAnimalsBinding siteReceptorCrosses GeneticGeneticsBinding SitesHaplotypeGenetic Complementation TestHistocompatibility Antigens Class IIComplementationHaplotypesJournal of immunogenetics
researchProduct

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

2015

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by…

medicine.medical_treatmentAPOPTOTIC CALRETICULIN EXPOSUREanti-tumor immunityimmunogenicityPHOTODYNAMIC THERAPY0302 clinical medicinetranslational medicineoncoimmunologyImmunology and AllergyCytotoxic T cellMedicineAnti-tumor immunity; Immunogenicity; Immunotherapy; Molecular medicine; Oncoimmunology; Patient prognosis; Translational medicine; Immunology; Immunology and Allergy0303 health sciencesanti-tumor immunity; immunogenicity; immunotherapy; molecular medicine; oncoimmunology; patient prognosis; translational medicineRIBOSOMAL-PROTEIN DIMERClassificationddc:3. Good health030220 oncology & carcinogenesisImmunogenic cell deathMolecular MedicineimmunotherapyACTIVATING POLYPEPTIDE-IIHIGH HYDROSTATIC-PRESSURElcsh:Immunologic diseases. AllergyANTICANCER IMMUNE-RESPONSESImmunology3122 Cancers610 Medicine & healthpatient prognosis03 medical and health sciencesImmune systemHUMAN TUMOR-CELLSFORMYL PEPTIDE RECEPTORS030304 developmental biologybusiness.industryTranslational medicineBiology and Life SciencesCYTOTOXIC T-LYMPHOCYTESImmunotherapyDendritic cellMolecular medicineNEGATIVE BREAST-CANCERImmunologyCancer cellmolecular dicine3111 Biomedicinebusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma.

2002

Heat shock proteins (HSP) are families of highly conserved proteins which are induced in cells and tissues upon exposure to extreme conditions causing acute or chronic stress. They exhibit distinct functions and have been implicated in the pathogenesis of a number of diseases, including cancer. A causal relationship between HSP expression and immunogenicity has been demonstrated in murine and human tumors and is also associated with the immune response. In order to investigate the correlation of HSP expression and their immunogenic potential in renal cell carcinoma (RCC), we here analyzed (i) the protein expression profile of various members of the HSP family in untreated and interferon (IF…

medicine.medical_treatmentBiologyurologic and male genital diseasesKidneyBiochemistryPathogenesisInterferon-gammaMiceImmune systemInterferonHeat shock proteinmedicineTumor Cells CulturedAnimalsHumansInterferon gammaElectrophoresis Gel Two-DimensionalMolecular BiologyCarcinoma Renal CellHeat-Shock ProteinsKidneyImmunogenicityEpithelial CellsKidney NeoplasmsNeoplasm ProteinsCytokinemedicine.anatomical_structureSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationImmunologyCancer researchmedicine.drugProteomics
researchProduct

Induction of Type-Specific Neutralizing Antibodies by Capsomeres of Human Papillomavirus Type 33

2001

Abstract The immunogenicity of capsomeres of human papillomavirus type 33 was evaluated in a dose–response analysis. Capsomeres were obtained free of capsids by expression of L1 carrying the single point mutation C427S. Neutralizing antibodies were detected using an in vitro pseudoinfection assay. Capsomeres induced type-specific, neutralizing antibodies in mice even in the absence of adjuvant. The neutralization titers of immune sera raised without adjuvant were 10- to 20-fold lower than those of antisera to virus-like particles, but virtually identical using Freund's adjuvant. These data indicate that capsomeres may substitute for virus-like particles in future vaccines when used with an …

medicine.medical_treatmentDose-Response Relationship ImmunologicEnzyme-Linked Immunosorbent AssayAntibodies ViralpapillomavirusNeutralizationMiceCapsidNeutralization Testsdose responseVirologymedicineAnimalsHumansPapillomaviridaeAntiserumMice Inbred BALB CbiologyImmunogenicityCapsomereVirionneutralizationvaccinationVirologyTiterCapsidbiology.proteincapsomeresImmunizationAntibodyAdjuvantVirology
researchProduct

Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation

2021

Abstract The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using in vitro as well as in vivo immunodeficient and immunocompetent murine multiple myeloma models, we here show that bortezomib also triggers immunogenic cell death (ICD), characterized by exposure of calreticulin on dying multiple myeloma cells, phagocytosis of tumor cells by dendritic cells, and induction of multiple myeloma–specific immunity. We identify a bortezomib-triggered specific ICD gene signature associated with better outcome in two independent cohorts of patients with multiple myeloma. Importantly, bortezomib stimulates multiple myeloma cell immunogen…

medicine.medical_treatmentIFNBortezomibMiceImmune systemimmune system diseaseshemic and lymphatic diseasesimmunogenic cell deathmedicineAnimalsHumansbortezomib myelomaMultiple myelomaBortezomibbusiness.industryImmunityMembrane ProteinsGeneral MedicineImmunotherapymedicine.diseaseNucleotidyltransferasesStingApoptosisCancer researchProteasome inhibitorImmunogenic cell deathMultiple MyelomabusinessSignal TransductionSTINGmedicine.drugBlood Cancer Discovery
researchProduct

HLA Class II Differentiates Between Thyroid and Polyglandular Autoimmunity.

2015

The HLA class II genes are susceptibility genes for autoimmune endocrine diseases; however, scarce data are available pertaining to the determinants of genetic susceptibility to polyglandular autoimmunity (PGA). A total of 300 consecutive and unselected patients with either PGA or monoglandular autoimmune thyroid disease (AITD) and 100 healthy control subjects were genotyped for the HLA class II DRB1, -DQA1, and -DQB1 alleles. Compared to patients with AITD and controls, the HLA-DRB1*03 (pc =0.001), *04 (pc<0.001), -DQA1*03 (pc<0.001), and -DQB1*02 (pc =0.001) alleles were increased in patients with PGA. When dividing patients with Hashimoto's thyroiditis (HT) into those with PGA (PGA-HT) v…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismGraves' diseaseClinical BiochemistryThyroid GlandAutoimmunityImmunogeneticsHashimoto Diseasemedicine.disease_causeBiochemistryThyroiditisAutoimmunityYoung AdultEndocrinologyInternal medicineGenetic predispositionMedicineHumansHashimoto DiseaseGenetic Predisposition to DiseaseAlleleskin and connective tissue diseasesChildbusiness.industryBiochemistry (medical)ThyroidHistocompatibility Antigens Class IIInfantGeneral MedicineMiddle Agedmedicine.diseaseGraves DiseaseEndocrinologymedicine.anatomical_structureChild PreschoolImmunologyFemalebusinessHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
researchProduct

Immune-mediated rippling muscle disease with myasthenia gravis: a report of seven patients with long-term follow-up in two.

2009

We report seven patients with immune-mediated rippling muscle disease (iRMD) and AChR-antibody positive myasthenia gravis (MG) without germline caveolin-3 gene mutations. We describe the follow-up of two patients and the clinical features of five new patients (1 female, 4 male, aged 32 to 69 years). These presented with significant generalized, exercise-induced and electrically-silent muscle rippling with myalgia, combined with generalized MG. In two of the seven patients, MG appeared before iRMD. Mediastinal imaging excluded thymic alterations in all, although two had other coincident tumours. Myalgia and rippling were aggravated by acetylcholinesterase-inhibitor treatment. Generalized MG …

myalgiaAdultMalePathologymedicine.medical_specialtyCaveolin 3Immunogenicmedicine.medical_treatmentMuscle Fibers SkeletalMuscle ProteinsCaveolin-3; Immunogenic; Myasthenia gravis; Rippling muscle disease; TherapyAzathioprineThymus GlandGene mutationBiologyCaveolaeDysferlinCaveolin-3Muscular DiseasesAzathioprineMyasthenia GravismedicineHumansMuscle SkeletalGenetics (clinical)AgedAutoantibodiesSarcolemmaElectromyographyAutoantibodyRippling muscle diseasePlasmapheresisMiddle Agedmedicine.diseaseMyasthenia gravisNeurologyPediatrics Perinatology and Child Healthbiology.proteinPlasmapheresisFemaleSteroidsTherapyNeurology (clinical)Cholinesterase Inhibitorsmedicine.symptommedicine.drugFollow-Up StudiesMuscle ContractionNeuromuscular disorders : NMD
researchProduct